SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Roger's 1998 Short Picks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marconi who wrote (11583)7/16/1998 8:43:00 AM
From: Franco Battista  Read Replies (1) of 18691
 
Hello Marconi. IMO Zonagen filing for FDA approval is a lose-lose situation for the company. If Vasomax is rejected, the stock tanks. If it is approved, it faces the competition of Viagra- an oral drug that has been on the market for almost six months and has the lion's share. Vasomax was approved in Mexico a few months back, and even though it sells much cheaper than Viagra, has been totally ignored. The FDA filing removes the speculation on the stock and forces Zonagen to face the realities of the market. Only problem IMO is the small float and manipulation on the stock making timing very difficult on this dog.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News